A Study of 2 Doses of MAP0010 in Asthmatic Children

NCT00697697 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

192

Enrollment

INDUSTRY

Sponsor class

Stopped Corporate decision

Conditions

Asthma

Interventions

DRUG: 0.135mg MAP0010
DRUG: 0.25mg MAP0010

Sponsor

Allergan

Collaborators

[object Object]